Report contents
At a glance
- Business model: Gilead sells branded prescription drugs, and HIV supplied $6.2 billion of $8.3 billion of third-quarter 2026 product sales, with Biktarvy alone at $4.1 billion. The strength is a high-margin, once-daily regimen franchise with entrenched prescriber habit; the obstacle is that internal research has not recently replaced what expires, so pipeline comes from acquisitions.
- Financial quality: Operating cash flow has stayed between $8.01 billion and $11.38 billion in every fiscal year from FY2021 to FY2025, and free cash flow between $7.42 billion and $10.80 billion, while reported net income swung to a $10.50 billion June 2026 quarterly loss on acquired R&D charges. Balance-sheet capacity is thinner: liabilities were 76.2% of assets at June 30, 2026, with $8.31 billion of goodwill against $11.74 billion of equity.
Business model
Business model: Biktarvy still pays about half the bills
Gilead sells branded prescription medicines, and one antiviral pays for most of the rest. Product sales rose 13% to $8.3 billion in the third quarter of 2026, the company reported on October 29, and HIV products supplied $6.2 billion of that, up 18%. Biktarvy alone brought in $4.1 billion, roughly half of everything Gilead sold in the quarter.
| Segment | Q3 2026 sales (USD m) | YoY change |
|---|---|---|
| HIV | 6,200 | +18% |
| Liver disease | 927 | +13% |
| Trodelvy | 506 | +42% |
| Cell therapy | 355 | -18% |
| Veklury | 86 | -69% |
| Total product sales | 8,300 | +13% |
The listed lines leave roughly $225 million of other products inside the total. Gilead's buyer is a payer, not a patient. In the US that means commercial insurers and government programs reimbursing list price less negotiated rebates, with patients covering modest copays; elsewhere national health systems set the price. The earnings release gives no payer mix, no gross-to-net bridge and no country-level split. For a company whose growth depends partly on realized price, that gap matters: without those numbers a reader cannot separate a list-price increase from lighter rebating. The business type is a brand manufacturer with a mature, heavily concentrated franchise, not a pipeline still proving itself. Veklury shows how quickly a demand pool can close, from pandemic-scale revenue to $86 million a quarter.
Price, volume, and a helpful inventory swing
Gilead credits the 18% HIV growth to three things: higher average realized price, higher demand in HIV prevention, and favorable inventory dynamics. Only one of those compounds reliably. Inventory moves reverse, and reported sales reflect shipments to wholesalers rather than pills dispensed, so a build can flatter a quarter. Annual price increases meet payer resistance and end at loss of exclusivity. Prevention is the durable piece, and the company said prevention sales nearly doubled year over year. Descovy's 49% jump to $1.0 billion came from price and inventory, with no demand driver cited in the release, so it says less about the franchise than the headline implies. Trodelvy's 42% gain rests on demand, a better quality of growth at a much smaller base.
Reported profitability is flattered in a similar way. Non-GAAP product gross margin of 88.1%, up from 86.5%, is mostly the expiration of a royalty obligation, a step that does not repeat, while R&D rose to $1.6 billion in the quarter. Liver disease grew 13% to $927 million on Livdelzi demand and higher hepatitis C and B prices, with hepatitis C volume still shrinking.
Buying what research has not produced
The number that best explains the model is not in the revenue line. Gilead spent $11.3 billion on acquisitions in the first nine months of 2026 against $11.2 billion of operating cash flow, having generated $5.0 billion of operating cash in the third quarter alone. The products throw off cash at a high rate, and roughly a full year of it went out the door to buy pipeline assets. High gross margin is real; so is the cost of refilling a concentrated, patent-protected portfolio. That is the tradeoff at the center of the business. Internal research built the HIV franchise, but it has not recently produced enough late-stage assets to replace what expires, so Gilead buys them.
Bargaining power sits with payers. US pharmacy benefit managers trade rebates for formulary position, and European systems set prices administratively. What Gilead holds is clinical data and prescriber habit: a once-daily single-tablet regimen patients stay on for years, plus a prevention franchise rivals must match with their own trials and coverage. Cell therapy, down 18% on what the company called competitive headwinds, is the one place where a competitor has visibly shrunk a Gilead franchise. At $355 million a quarter it is small, but it was meant to be the second leg.
What would overturn the judgment
If HIV growth excluding inventory falls to single digits while prevention sales stop doubling, the base business is a price-led story heading into patent expiries, and the acquisition budget becomes the real engine. The test is the next two quarters: whether prevention keeps adding volume and Biktarvy holds prescription share while price contributes. Cell therapy is the second check; a third consecutive double-digit decline would leave oncology resting on Trodelvy alone, at about an eighth of HIV revenue.
Questions worth following
- How much US pricing power can Gilead keep in HIV as Medicare negotiation and payer pressure build?
US payer leverage sets net price, and Medicare negotiation can impose a public benchmark other payers reference. A favorable answer means the HIV franchise keeps funding investment; an unfavorable one compresses the cash flow supporting the whole portfolio and raises the urgency of the oncology build-out.
- Can HIV prevention demand keep Gilead's HIV growth in double digits?
Gilead said prevention sales nearly doubled year over year and counted prevention demand in its 18% HIV growth. Prevention is the volume engine that can outlast price increases, so its scale decides whether HIV growth survives a tougher pricing environment.
- Can Gilead's cell therapy franchise stop losing ground to rivals?
Cell therapy sales fell 18% on what the company called competitive headwinds, and the franchise was meant to give Gilead a second leg beyond antivirals. Continued decline would leave oncology dependent on Trodelvy and raise questions about the manufacturing and commercial investment behind it.
Financial quality
Financial quality: cash holds up while reported earnings swing
Gilead's cash generation is the dependable part of the story; its income statement is not. Net income ran from $6.22 billion in FY2021 to $8.51 billion in FY2025, but along the way it fell to $0.48 billion in FY2024 and to a $10.50 billion loss in the June 2026 quarter, while operating cash flow never dropped below $8.01 billion in a fiscal year. Acquired in-process R&D, marks on equity securities and acquisition accounting explain most of that gap. Cash is the right anchor for a quality judgment; the earnings line mostly tells you what Gilead pays to refill its pipeline.
Margins are excellent; returns are harder to read
| USD bn | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Q2 FY2026¹ | Assessment |
|---|---|---|---|---|---|---|---|
| Revenue | 27.30 | 27.28 | 27.12 | 28.75 | 29.44 | 7.80 | Adequate |
| Operating income | 9.92 | 7.33 | 7.60 | 1.66 | 11.70 | -10.39 | Weak |
| Net income | 6.22 | 4.59 | 5.67 | 0.48 | 8.51 | -10.50 | Weak |
| Gross margin % | 75.8 | 79.3 | 100.0² | 78.3 | 78.8 | 79.7 | Exceptional |
| Net margin % | 22.8 | 16.8 | 20.9 | 1.7 | 28.9 | -134.6 | Weak |
| ROE % | 31.7 | 21.7 | 25.7 | 2.3 | 40.5³ | n.m. | Adequate |
| ROA % | 9.1 | 7.0 | 9.0 | 0.8 | 14.4³ | n.m. | Adequate |
| EBIT/assets % | 13.7 | 10.7 | 12.2 | 2.8 | 18.3³ | n.m. | Adequate |
| Liabilities/assets % | 69.0 | 66.4 | 63.4 | 67.4 | 61.7 | 76.2 | Weak |
| Current ratio | 1.27 | 1.29 | 1.43 | 1.60 | n/d | n/d | Adequate |
| Operating cash flow | 11.38 | 9.07 | 8.01 | 10.83 | 10.02 | 3.57 | Strong |
| Capex/revenue % | 2.1 | 2.7 | 2.2 | 1.8 | 1.9 | n.m. | — |
| Free cash flow | 10.80 | 8.34 | 7.42 | 10.30 | 9.46 | 3.69⁴ | Strong |
| OCF/net income (x) | 1.8 | 2.0 | 1.4 | 22.6 | 1.2 | n.m. | Strong |
¹ Three months ended June 30, 2026; flow items are not comparable with annual columns. ² The source shows gross profit equal to revenue; adjacent years put the true level near 78%. ³ Calculated from reported income and average equity or year-end assets. ⁴ Exceeds operating cash flow because reported capex is negative in the period.
Gross margin held at 76–80% in every year and reached 81.0% in Q3 2026, up from 78.6%, as a royalty obligation expired, the company said in its October 29, 2026 release. R&D of $1.6 billion that quarter was roughly 19% of product sales, appropriate for a business that must replace a large HIV franchise. The return series is muddier. EBIT/assets swung from 13.7% in FY2021 to 2.8% in FY2024 and back to 18.3% in FY2025, tracking charges more than pricing. The 40.5% ROE calculated for FY2025 rests on $8.51 billion of income over about $21 billion of average equity supporting $59 billion of assets; with equity down to $11.74 billion at June 30, 2026, any ROE struck on that base would say more about the denominator than about the business.
Cash conversion is the strong part, with one caveat
Operating cash flow covered net income 1.4 to 2.0 times in FY2021 through FY2023 and 1.18 times in FY2025; the 22.6x of FY2024 is a shrunken denominator, not a cash windfall. Capex has stayed near 2% of revenue, so free cash flow tracks operating cash flow closely: $7.42 billion to $10.80 billion every year for five years. The caveat is definitional. Gilead's real investment is acquisitions, and those sit in investing cash flow, outside free cash flow.
In the first nine months of 2026 the company spent $11.3 billion on acquisitions against $11.2 billion of operating cash flow, according to the October release. It also repaid $2.8 billion of debt, paid $3.1 billion of dividends and repurchased $1.1 billion of stock, partly funded by $4.1 billion of net new borrowing. When deal flow is heavy, deals and distributions together exceed internal cash and the balance sheet closes the gap. The June 30 position showed the strain: liabilities at 76.2% of assets and $3.18 billion of cash against $11.02 billion of current liabilities. By September 30, cash, cash equivalents and marketable securities were $6.4 billion and quarterly operating cash flow was $5.0 billion, so most of that squeeze was timing.
Six quarters: one charge, one acquisition
| USD bn | Revenue | Net income | Gross margin % | Op. cash flow | Total assets | Total liabilities | Equity | Cash | Assessment | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2025 | 6.67 | 1.31 | 76.9 | 1.76 | 56.43 | 37.36 | 19.16 | 7.93 | Adequate | Stable |
| Q2 2025 | 7.08 | 1.96 | 78.8 | 0.83 | 55.72 | 36.13 | 19.68 | 5.14 | Adequate | Revenue up, cash soft |
| Q3 2025 | 7.77 | 3.05 | 79.8 | 4.11 | 58.53 | 37.08 | 21.54 | 7.33 | Strong | Improving |
| Q4 2025 | 7.92 | 2.18 | 79.5 | 3.33 | 59.02 | 36.41 | 22.70 | 7.56 | Strong | Stable |
| Q1 2026 | 6.96 | 2.02 | 79.2 | 2.54 | 56.28 | 32.85 | 23.52 | 7.63 | Adequate | Seasonal dip |
| Q2 2026 | 7.80 | -10.50 | 79.7 | 3.57 | 49.36 | 37.62 | 11.74 | 3.18 | Weak | Deteriorating |
Net PP&E is not disclosed for any of these quarters.
The June 2026 quarter shows why the two statements diverge. Revenue rose to $7.80 billion from $7.08 billion a year earlier and gross margin held at 79.7%, yet the quarter produced a $10.50 billion loss and a $10.35 billion investing outflow. The operating loss of $10.39 billion against $6.22 billion of gross profit points to acquired R&D being expensed rather than capitalized, though the income statement does not break out that line; the operating quarter itself did not deteriorate.
What needs checking
- Recurring charges booked as one-time. FY2024 operating income was $1.66 billion on $22.5 billion of gross profit, and Q3 2026 non-GAAP EPS of $2.55 compared with GAAP $1.94. If acquired R&D appears in most years, adjusted EPS overstates earnings power and the free cash flow figure overstates what is available to shareholders. Gilead publishes no fixed annual deal budget, so the run rate has to be inferred from the cash flow statement.
- Price and channel inventory. Third-quarter HIV sales rose 18% to $6.2 billion on higher realized price and "favorable inventory dynamics," with Descovy up 49% on the same drivers. Neither is repeatable volume. Prescription trends and wholesaler inventory will show whether underlying demand matches reported sales.
- Goodwill against thin equity. The $8.31 billion of goodwill has not moved since FY2022 and now equals about 70% of book equity. Cell therapy sales fell 18% on competitive headwinds. An impairment would not touch cash but would cut equity further and reset the ROE base.
- Liquidity timing. The September recovery depended on new borrowing. The maturity ladder and the pace of any resumed buybacks decide whether funding stays comfortable.
Questions worth following
- Is acquired IPR&D a recurring cost that caps Gilead's earnings power?
Gilead books large acquired R&D charges in some years and almost none in others, so GAAP and adjusted earnings tell different stories. Whether the charge recurs at a meaningful run rate decides which earnings base deserves the multiple and how much cash is genuinely free for distributions.
Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.
Continue reading the full report
- Key risksWhat could break the investment case
- Valuation and margin of safetyWhat the current price assumes, and how much room for error it leaves
- SummaryOur overall judgement and what to watch next
Free to sign up · 20 research points · unlocking this report uses 10
20 points cover 2 full reports. No card needed.
Research reflects its generation date. Preview the first two modules.
More on Gilead Sciences Inc
Gilead Sciences Inc
Business, moat and key questions
Open company page